Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Baidu Inc (BIDU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Baidu Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Baidu Inc trades at $117.33 (market cap $38.39B). The key difference: Baidu Inc is far larger — about 8.6× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Baidu Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BIDU | |
|---|---|---|
Market Cap | $4.49B | $38.39B |
Sector | Health | Media |
52-Week High | $28.06 | $162.52 |
52-Week Low | $20.06 | $85.86 |
Enterprise Value | $3.69B | $35.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BIDU trades at $112.09, down 1.07% today, with a neutral technical signal and bearish moving averages. Recent earnings show a Q1 2026 miss after two consecutive beats, while revenue declined to $129.08B in 2025. The stock holds a strong buy consensus from analysts with a $177.50 price target, supported by AI-driven optimism including Kunlunxin's potential $50B Hong Kong IPO reported by Reuters on June 28, 2026.
BIDU presents a high-risk, high-reward opportunity with its AI pivot accelerating but facing profitability pressures. The 78.19 P/E ratio suggests premium valuation, yet net margins compressed to 1.02% in 2025. Key risks include regulatory scrutiny and competitive threats, while institutional sentiment remains bullish with 75% buy ratings. Upside hinges on AI monetization offsetting legacy search declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Baidu Inc
Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.
Read more on BIDU →
